In advanced chemo-refractory NSCLC, the introduction of entinostat to erlotinib presented no overall benefit compared to erlotinib alone, yet appeared to enhance survival in a subgroup of patients with high tumour E-cadherin levels at diagnosis [70,71]. The gene discussed is CDH1; the disease is non-small cell lung carcinoma.